Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Gross Margin (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Gross Margin for 6 consecutive years, with 43.55% as the latest value for Q4 2025.

  • Quarterly Gross Margin rose 351.0% to 43.55% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 56.97% through Dec 2025, up 1763.0% year-over-year, with the annual reading at 56.67% for FY2025, 1733.0% up from the prior year.
  • Gross Margin hit 43.55% in Q4 2025 for Insight Molecular Diagnostics, down from 53.46% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 72.47% in Q4 2021 to a low of 401.49% in Q3 2022.
  • Historically, Gross Margin has averaged 5.26% across 5 years, with a median of 41.76% in 2024.
  • Biggest five-year swings in Gross Margin: surged 98828bps in 2021 and later plummeted -31348bps in 2022.
  • Year by year, Gross Margin stood at 72.47% in 2021, then crashed by -114bps to 9.85% in 2022, then plummeted by -278bps to 37.26% in 2023, then skyrocketed by 207bps to 40.04% in 2024, then rose by 9bps to 43.55% in 2025.
  • Business Quant data shows Gross Margin for IMDX at 43.55% in Q4 2025, 53.46% in Q3 2025, and 67.57% in Q2 2025.